Rondy, MarcKissling, EstherEmborg, Hanne-DortheGherasim, Alin ManuelPebody, RichardTrebbien, RamonaPozo Sanchez, FranciscoLarrauri, AmparoMcMenamin, JimValenciano, MartaI-MOVE/I-MOVE+ groupDelgado-Sanz, ConcepcionOliva Dominguez, Jesus AngelCasas Flecha, Inmaculada2020-01-302020-01-302018Euro Surveill. 2018 Mar;23(9):18-00086.1560-7917http://hdl.handle.net/20.500.12105/8992Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.engVoRhttp://creativecommons.org/licenses/by/4.0/EuropeCase control studyInfluenzaInfluenza vaccinationInfluenza vaccine effectivenessMulticentre studyAdolescentAdultAgedChildChild, PreschoolEuropeEuropean UnionFemaleHumansInfantInfant, NewbornInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza B virusInfluenza VaccinesInfluenza, HumanMaleMiddle AgedPandemicsTreatment OutcomeVaccinationSeasonsAtribución 4.0 Internacional2951078223910.2807/1560-7917.ES.2018.23.9.18-000861560-7917Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinopen access